NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis $11.46 -0.61 (-5.05%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$11.46▼$12.0350-Day Range$10.13▼$14.6052-Week Range$9.93▼$23.75Volume340,600 shsAverage Volume424,159 shsMarket Capitalization$660.90 millionP/E Ratio9.47Dividend Yield5.24%Price Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Embecta alerts: Email Address Embecta MarketRank™ Stock AnalysisAnalyst RatingReduce1.50 Rating ScoreUpside/Downside13.4% Upside$13.00 Price TargetShort InterestBearish6.16% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth2.17%From $2.30 to $2.35 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.74 out of 5 starsMedical Sector599th out of 879 stocksSurgical & Medical Instruments Industry72nd out of 95 stocks 1.8 Analyst's Opinion Consensus RatingEmbecta has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageEmbecta has only been the subject of 1 research reports in the past 90 days.Read more about Embecta's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.16% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Embecta has recently increased by 22.43%, indicating that investor sentiment is decreasing significantly. Previous Next 3.3 Dividend Strength Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 5.24%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 49.59%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 25.53% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EMBC. Previous Next 2.3 News and Social Media Coverage News SentimentEmbecta has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Embecta this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for EMBC on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.28% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Embecta are expected to grow by 2.17% in the coming year, from $2.30 to $2.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 9.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.49.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 9.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 110.17.Read more about Embecta's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).Get the full story here while you can. About Embecta Stock (NASDAQ:EMBC)Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Read More EMBC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EMBC Stock News HeadlinesJuly 7 at 2:42 AM | americanbankingnews.comEmbecta (NASDAQ:EMBC) Shares Gap Down to $12.07June 24, 2024 | globenewswire.comembecta-sponsored Abstracts Presented at American Diabetes Association's 84th Scientific Sessions Highlight Unmet Need for Patch Pumps with 300u Insulin ReservoirJuly 8, 2024 | Stansberry Research (Ad)BUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).June 20, 2024 | prnewswire.comZimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of DirectorsMay 21, 2024 | investorplace.comTrade Winds Turning: 3 Stocks Poised to Gain from Biden's China TariffsMay 13, 2024 | finance.yahoo.comEmbecta Corp. (NASDAQ:EMBC) Q2 2024 Earnings Call TranscriptMay 13, 2024 | seekingalpha.comEmbecta Corp. (EMBC) Q2 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comEmbecta Corp (EMBC) Surpasses Analyst Revenue Forecasts in Q2 Fiscal 2024July 8, 2024 | Stansberry Research (Ad)BUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).May 10, 2024 | finance.yahoo.comEmbecta Second Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | marketwatch.comEmbecta Shares Rise After 2Q Results, Higher FY GuidanceMay 9, 2024 | globenewswire.comEmbecta Corp. Reports Second Quarter Fiscal 2024 Financial ResultsMay 9, 2024 | globenewswire.comembecta Announces Quarterly Cash DividendMay 8, 2024 | markets.businessinsider.comEmbecta earnings preview: what Wall Street is expectingMay 4, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Embecta StockMay 1, 2024 | globenewswire.comembecta to Participate in Investor EventsApril 23, 2024 | globenewswire.comembecta to Report Fiscal Second Quarter 2024 Financial ResultsApril 16, 2024 | finance.yahoo.comEmbecta Corp. (EMBC) Stock Historical Prices & Data - Yahoo FinanceSee More Headlines Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Ex-Dividend for 6/14 Dividend5/24/2024Dividend Payable6/14/2024Today7/08/2024Next Earnings (Estimated)8/13/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:EMBC CUSIPN/A CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees2,200Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$13.00 Low Stock Price Target$13.00 Potential Upside/Downside+13.4%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.21 Trailing P/E Ratio9.47 Forward P/E Ratio4.98 P/E GrowthN/ANet Income$70.40 million Net Margins6.20% Pretax Margin4.35% Return on Equity-18.42% Return on Assets12.05% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick Ratio1.79 Sales & Book Value Annual Sales$1.13 billion Price / Sales0.58 Cash Flow$3.70 per share Price / Cash Flow3.10 Book Value($14.34) per share Price / Book-0.80Miscellaneous Outstanding Shares57,670,000Free Float57,509,000Market Cap$660.90 million OptionableOptionable Beta0.99 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Devdatt Kurdikar (Age 56)President, CEO & Director Comp: $2.2MMr. Jacob P. Elguicze (Age 51)Senior VP & CFO Comp: $1.05MMr. Brian R. Capone (Age 49)VP, Chief Accounting Officer & Corporate Controller Comp: $645.16kMr. Jeffrey Z. Mann (Age 52)Senior VP, General Counsel, Head of Business Development & Corporate Secretary Comp: $959.45kMr. Shaun Curtis (Age 55)Senior Vice President of Global Manufacturing & Supply Chain Comp: $915.67kMs. Colleen Riley (Age 60)Senior VP & Chief Technology Officer Mr. Pravesh KhandelwalVP & Head of Investor RelationsMs. Ginny BlockiSenior Vice President of Global Marketing & Product ManagementMs. Jean M. Casner (Age 66)Senior VP & Chief Human Resources Officer Mr. Tom Blount (Age 50)Senior VP & President of North America More ExecutivesKey CompetitorsTandem Diabetes CareNASDAQ:TNDMIntegra LifeSciencesNASDAQ:IARTUFP TechnologiesNASDAQ:UFPTLeMaitre VascularNASDAQ:LMATNovoCureNASDAQ:NVCRView All CompetitorsInsiders & InstitutionsCacti Asset Management LLCSold 54,050 shares on 6/3/2024Ownership: 0.006%Comerica BankSold 63,990 shares on 5/17/2024Ownership: 0.043%Jacobs Levy Equity Management Inc.Bought 313,951 shares on 5/16/2024Ownership: 1.115%California State Teachers Retirement SystemSold 2,963 shares on 5/16/2024Ownership: 0.100%Bayesian Capital Management LPBought 1,500 shares on 5/16/2024Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions EMBC Stock Analysis - Frequently Asked Questions How have EMBC shares performed this year? Embecta's stock was trading at $18.93 at the beginning of 2024. Since then, EMBC stock has decreased by 39.5% and is now trading at $11.46. View the best growth stocks for 2024 here. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) posted its quarterly earnings results on Thursday, May, 9th. The company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.24. The business's revenue was up 3.6% compared to the same quarter last year. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EMBC) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.